While gain-of-function mutations in ESR1, the gene encoding ERα, are relatively rare in primary breast cancer [42], 11–55% of metastatic cancers have point mutations in the ligand-binding domain of ER, especially in amino acids Y537 and D538 [42]. This evidence concerns the gene ESR1 and breast carcinoma.